About Stephen Strittmatter
Stephen Strittmatter is the scientific founder of Allyx Therapeutics. He is also a director. Allyx develops oral small-molecule medicines that aim to protect synapses, the connections between brain cells, in neurodegenerative diseases. He holds the Vincent Coates professorship in neurology at Yale University. His research found that a targeted compound reversed the disease course in animal models of Alzheimer’s disease.
By 2019, he had founded ReNetX Bio and was serving as its scientific advisor. ReNetX developed AXER-204 for chronic spinal cord injury. Its approach blocks inhibitory proteins to promote nerve-cell regrowth.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Stephen Strittmatter in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Stephen Strittmatter works with at each company, as listed on that company's latest Form D.
